Most patients with psoriasis experienced clinical improvement or remission after metabolic and bariatric surgery (MBS) in a ...

Background: Psoriasis is a chronic inflammatory skin disease with a genetic predisposition and autoimmune component, often treated with immunomodulators such as biologic therapies. Objectives: In this ...

Whether you suffer from psoriasis yourself or have heard about it from a famous Kardashian who has been very transparent about her symptoms, you know that the skin condition is far from glamorous and ...

Topical treatments, such as ointments and creams, are often the first-line treatment for people with psoriasis, according to the National Psoriasis Foundation (NPF). As psoriasis progresses or ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. By week 8, patients treated with roflumilast saw ...

SAN DIEGO — Disease-modifying antirheumatic drugs (DMARDs) and biologics were linked to as much as a 74.5% reduction in the risk for alopecia areata (AA) in patients with psoriasis, a new ...

The psoriasis patient group consisted of 32 females and 32 males, and the control group consisted of 28 females and 29 males. Disease types were classified as plaque, palmar, guttate, erythrodermic, ...

Between 61% to 82% of patients with atopic dermatitis, psoriasis, and xerosis reported improvement in their symptoms following 4 weeks of using a ceramide-containing skin care regimen. Researchers ...

66% of patients with scalp psoriasis achieved a scalp-specific Investigator's Global Assessment (ss-IGA) c score of 0/1 compared to 11% receiving placebo (P<0.001) at 16 weeks.

Tis the season for good cheer, good friends, good food ... and, if you have psoriasis, a good chance that your skin condition will worsen. There are some lucky souls who don’t find the holidays ...

Roflumilast foam 0.3% applied once daily led to significantly greater clearance of scalp and body plaque psoriasis lesions and more rapid itch reduction than placebo over eight weeks.

In 2022, a drug called deucravacitinib was approved by the U.S. Food and Drug Administration to treat psoriasis. This medication targets TYK2 in a way that stops its ability to relay harmful ...